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Summary
The molecular mechanisms behind aging-related declines in
muscle function are not well understood, but the growth factor
myostatin (MSTN) appears to play an important role in this
process. Additionally, epidemiological studies have identified a
positive correlation between skeletal muscle mass and longevity.
Given the role of myostatin in regulating muscle size, and the
correlation between muscle mass and longevity, we tested the
hypotheses that the deficiency of myostatin would protect
oldest-old mice (28–30 months old) from an aging-related loss
in muscle size and contractility, and would extend the maximum
lifespan of mice. We found thatMSTN+/ andMSTN/mice were
protected from aging-related declines in muscle mass and
contractility. While no differences were detected between
MSTN+/+ andMSTN/ mice,MSTN+/ mice had an approximately
15% increase in maximal lifespan. These results suggest that
targeting myostatin may protect against aging-related changes in
skeletal muscle and contribute to enhanced longevity.
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tractility; myostatin; sarcopenia; skeletal muscle.
Sarcopenia is the pathological loss in muscle mass and strength that
occurs with aging (Gumucio & Mendias, 2013). In mice, muscle mass
and force production slowly decreases from adulthood (6–9 months of
age) to old age (22–24 months), with a rapid deterioration present once
mice reach oldest-old ages (>26–28 months) (Brooks & Faulkner, 1988;
Lynch et al., 2001; Graber et al., 2013). There is also an aging-
associated increase in collagen accumulation which can diminish force
production (Ramaswamy et al., 2011). In humans, muscle mass is
positively correlated with a greater longevity (Miller et al., 2002), and the
rapid decrease in muscle mass and strength that occurs toward the end
of the lifespan can lead to severe disability and reduced quality of life
(Fielding et al., 2011).
Myostatin is a negative regulator of skeletal muscle mass, with
adult MSTN/ mice displaying up to a twofold increase in muscle
mass (Gumucio & Mendias, 2013). Myostatin induces atrophy by
upregulating the E3 ubiquitin ligases atrogin-1 and MuRF-1 and by
inhibiting the IGF-1 pathway (Gumucio & Mendias, 2013). As the role
of myostatin in regulating muscle function in oldest-old mice had not
previously been studied, and there is a positive correlation between
muscle mass and longevity in humans (Miller et al., 2002), we tested
the hypotheses that oldest-old male myostatin-deficient mice would
have improved muscle force production compared to wild-type mice
and that the deficiency of myostatin would increase the maximum
lifespan of mice.
Circulating myostatin protein was not detectable in MSTN/mice,
while MSTN+/ mice had a 30% decrease (Table S1). For the fast-fibered
EDL, MSTN+/ and MSTN/ mice had a greater mass (Fig. 1A) and
number of type II muscle fibers (Fig. S1) than controls. Maximum
isometric force production (Po) was increased in MSTN
+/ and MSTN/
mice (Fig. 1B), although no differences in specific force production (sPo),
which is Po normalized to muscle cross-sectional area (CSA), were noted
(Fig. 1C). Atrogin-1 was decreased in MSTN/ mice, but no other
differences in MuRF-1 were observed (Fig. 1D–E).
For mixed-fiber soleus muscles, MSTN/ mice had increased mass
(Fig. 1H). No change in the percent distribution of fiber types or fiber
CSA was observed, although there was an increase in the number of
fibers inMSTN+/ andMSTN/mice (Fig. S1). Interestingly, despite both
MSTN+/ and MSTN/ mice demonstrating a substantial increase in Po
(Fig. 1I), only the MSTN+/ mice had an increase in sPo (Fig. 1J). No
differences in atrogin-1 or MuRF-1 expression were observed (Fig. 1K–L).
The differences between muscle mass and Po across the three genotypes
are also similar to previous reports in adult animals, but sPo was only
elevated in adult MSTN/ mice (Mendias et al., 2006) unlike in the
current study. Combined, these results suggest the prolonged deficiency
of myostatin protects against the aging-associated decrease in Po
without having a negative impact on sPo in oldest-old mice. Further, as
fiber loss is considered to be the primary contributor to aging-associated
muscle atrophy (Gumucio & Mendias, 2013), there appears to be a
protective effect of myostatin deficiency on the primary cause of aging-
related muscle weakness.
We next evaluated changes in the muscle ECM, as myostatin can
directly induce collagen expression in muscle and fibroblast cells
(Mendias et al., 2006, 2008). Hydroxyproline, which is a marker of
collagen, and type I collagen expression were reduced in EDL muscles
of MSTN+/ and MSTN/ mice (Fig. 1F–G). For soleus muscles,
MSTN+/ and MSTN/ mice had a reduction in hydroxyproline,
although no change in type I collagen expression was detected
(Fig. 1M–N). This reduction in collagen is consistent with findings in
adult animals (Mendias et al., 2006), and the reduction in collagen
levels in oldest-old mice may contribute to their improved contractile
properties.
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In the lifespan study, there were no differences between the survival
curves ofMSTN+/+ andMSTN/mice, butMSTN+/mice had significant
different survival curves from MSTN+/+ and MSTN/ mice (Fig. 2A).
MSTN+/ mice also had an increase in maximal lifespan and maximum
age (Fig. 2B). Approximately 2/3 of mice could be submitted to
necropsy, and the only pathological finding of significance was gross
cardiomegaly. No differences in relative heart mass were present
between MSTN+/+ and MSTN+/ mice, but there was an increase
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Fig. 1 Muscle contractility, hydroxyproline and gene expression values of EDL muscles (A through G) and soleus muscles (H through N) from 28- to 30-month old MSTN+/+,
MSTN+/ and MSTN/ mice. (A, H): Wet mass. (B, I): Maximum isometric force (Po). C, J: Specific force (sPo). Gene expression for (D, K) Atrogin-1, (E, L) MuRF-1 and
(F, M) Type 1 collagen. G, N: Hydroxyproline content. Values are mean  SE; N = 6 mice per genotype. Differences tested with a one-way ANOVA and Fisher’s LSD post hoc
sorting. *, different from MSTN+/+ (P < 0.05). #, different from MSTN+/ (P < 0.05).
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observed in MSTN/ mice (Fig. 2B). Although we did not evaluate
female mice in this study, we do not anticipate sex-specific differences in
these findings.
Mouse strains with loss of function in the growth hormone/IGF-1 axis
have a smaller body size and enhanced lifespan (Blagosklonny, 2013). The
current results are the first to identify a loss of function gene mutation in
mice that results in an increase in muscle and body mass along with
enhanced longevity. The mechanism behind the increased longevity of
MSTN+/ mice is not known, but inhibition of myostatin can reduce
systemic inflammatory proteins and body fat (Gumucio & Mendias,
2013). Given the increase in relative heart mass, the contribution of
aging-associated cardiomegaly to mortality (Lakatta & Levy, 2003) and
that inhibition of myostatin can increase heart mass (Bish et al., 2011), it
is possible that positive effects of increased skeletal muscle mass on the
longevity of MSTN/ mice was offset by cardiac pathologies.
Most genetic models of enhanced longevity in mice have identified an
inverse relationship between body mass and longevity, which has lead to
the observation that ‘big mice die young’ (Blagosklonny, 2013).
However, the results from the current study support the epidemiological
observations in humans that when it comes to skeletal muscle mass and
longevity, bigger may be better.
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Data S1 Experimental procedures.
Fig. S1 Histology for EDL muscles (A through C) and soleus muscles (D
through H) from 28 to 30 month old MSTN+/+, MSTN+/ and MSTN/ mice.
Table S1 Morphological and contractile properties measurements.
Table S2 Lifespan data.
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MSTN+/+ MSTN+/– MSTN–/–
Mean lifespan 25.7 ± 1.1 (39) 28.2 ± 1.3 (42) 24.5 ± 1.3 (38)
Maximum lifespan 34.1 ± 0.9 (4) 39.5 ± 1.2 (4)* 34.6 ± 0.6 (4)#
25th percentile 23.6 27.6 20.9
Median lifespan 26.9 29.7 26.3
75th percentile 29.4 33.3 29.8
Oldest age 36.2 43.0 36.1
Heart mass at death (mg) 209.8 ± 11.1 (27) 252.8 ± 9.9 (26)* 284.0 ± 13.3 (24)*
Body mass at death (g) 32.8 ± 1.4 (27) 37.1 ± 1.2 (26)* 34.2 ± 1.3 (24)
Normalized heart mass (mg/g) 6.38 ± 0.17 (27) 6.81 ± 0.12 (26) 8.32 ± 0.21 (24)*#
(A) (B)
Fig. 2 Lifespan data for MSTN+/+, MSTN+/ and MSTN/ mice. (A) Survival curves of mice. Log-rank analysis of survival curves: MSTN+/+ vs. MSTN/, P = 0.85; MSTN+/+
vs. MSTN+/, P = 0.003; MSTN+/ vs. MSTN/, P = 0.003. (B) Summary longevity and cardiac data. Values are mean  SE (N). Differences tested with a one-way
ANOVA and Fisher’s LSD post hoc sorting. *, different from MSTN+/+ (P < 0.05). #, different from MSTN+/ (P < 0.05).
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